Nerviano Medical Sciences (NMS) ADC Business Unit Portfolio Head, Rosita Lupi, delivered an oral presentation at the Festival of Biologics in Basel (30/09/2025):
“Reinventing Cytotoxins and Targeted Molecules as Next-Generation Payloads for ADCs.”
The session was very well received, with a full room of attendees engaged in the discussion—highlighting the strong interest in our approach to ADC innovation.
At NMS, we are advancing a payload-driven ADC and PDC platform that reinvents both validated and novel cytotoxic classes—turning them into differentiated payloads with greater safety, efficacy, and versatility. These payloads directly power our progressing ADC pipeline, designed to address unmet medical needs across multiple solid tumors.
Our three next-generation IP protected payload families include:
- Duocarmycins → engineered for durable efficacy and improved safety in chemoresistant, heterogeneous tumors.
- Anthracyclines → optimized for potency and tolerability, uniquely inducing immunogenic cell death and long-term antitumor immunity.
- Targeted Payloads → novel small molecules that we have successfully translated into payloads, overcoming intrinsic challenges of stability, potency, and conjugation. They disrupt oncogenic pathways, remain active in MDR and non-proliferating cells, and provide strong potential for dual-payload ADCs.
With these advances, our ADC pipeline is steadily moving forward to expand targetable tumor types, overcome resistance, and deliver durable responses.
We are proud to share this progress from Basel, reflecting our mission to shape the future of ADC innovation and deliver value for patients.
Explore our poster here
